CA-RECOVER
7.7.2021 18:53:08 CEST | Business Wire | Press release
Three leading companies in the textiles industry, Recover™, Happy Punt, and Hansae, have entered into a multi-year partnership agreement to provide end-to-end solutions for the design, development, and production of sustainably conscious apparel for the fashion industry. The partnership allows retailers and brands to seamlessly integrate sustainable Recover™ recycled cotton fiber into their products, thereby helping to solve one of the world’s biggest environmental issues.
Using innovative technology, the partnership provides a range of services, including 3D design, patterns, tech packs, samples, and production to support brands and retailers at every step in the supply chain. The partnership offers a unique speed to market solution for the production of fully sustainable apparel and leverages the group’s global reach, with offices in Seoul, Barcelona, and New York. In addition, close customer proximity provides in-market technical design services that develop, review and approve all specifications to ensure correct fit and brand enhancing products.The partnership also provides an end-to-end service that combines the advantages of production nearshore and offshore worldwide.
Dedicated leading edge design and development facilities can produce samples in house from concept to finished sample with a quick turnaround time. Notably, as part of a joint sustainability initiative, the partnership also encourages R&D designs to be replaced by 3D designs to reduce the environmental impact of the sampling process.
The three leading companies have a combined experience of over 130 years in each of their respective fields. Each firm’s commitment to bringing the best technology to the product and the market offers a disruptive approach to the traditional apparel design and production process. The partnership is proud to be actively working with leading global brands to deliver sustainable collections to the market by Spring 2022, and more collections are expected to follow.
Recover™ will increase its production to 200,000 metric tons of recycled cotton fiber per year by 2025 to support the current market demand. This recycled cotton volume will save nearly three trillion liters of water each year, equivalent to the drinking water consumed by 3 billion people on an annual basis and allow 500,000 acres of land to be directed away from cotton cultivation to other uses.
The Recover™, Happy Punt, and Hansae strategic partnership provides brands and retailers with an easy plug & play solution to achieve their sustainability initiatives and ensures a quality product for the consumer.
About Recover™
Recover™ is a leading material sciences company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all.
As a fourth-generation, family-owned company with over a 70-year history in the textile industry, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
For more information, visit www.recovertex.com and follow @recoverfiber on social media.
About Happy Punt
Happy Punt is a design and manufacturing end-to-end solution provider to the fashion industry, applying virtual design tools supported by the best technology offering an efficient and sustainable product development and design process. Founded in 1996, Happy Punt has more than 25 years of history in the fashion business, and a team of 80 fashion designers and PD&D. Happy Punt offers a “Gold Standard” of excellence in technical and production know-how that ensures the manufacturing and delivery of safe and reliable products by providing a global end-to-end service recognized for the quality of their fashion design and for the speed of their creative process.
About Hansae
Established in 1982, Hansae Co., Ltd. has maintained consistent growth through specialized apparel exports and annually produces over 300 million garments. Hansae has 14 global corporations in 7 countries, over 600 people at the corporate Headquarters, and over 35,000 in the global manufacturing workforce.
Its mission is to enrich customer’s lives and lead fashion culture by providing the best quality clothes at a reasonable price. Quality management systems maximize values for its customers by ensuring manufacturing excellence and on-time, safe delivery of products.
Hansae has developed HAMS, its own smart factory system to maximize the efficiency of production plants in Vietnam, Indonesia, Myanmar, Nicaragua, Guatemala, and Haiti.
Hansae aims to be a front-runner in sustainable management by establishing ‘10% For Good’, pledging to donate 10 percent of its net profits from sustainable orders to third parties that work toward improving ocean environment by collecting wastes, the advancement of green raw materials, and hardware upgrades and retrofits.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005776/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
